Furthermore, we explore emerging strategies, including gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective, unbiased pain assessment and research.
First-pass extracted concept
AI-driven pain assessment
Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
The review states that these innovative approaches are poised to enable discovery of safer and more effective analgesics.
Quoted textsource-backed
These innovative approaches are poised to revolutionize pain management, paving the way for the discovery of safer and more effective analgesics.
Opioid-dominated acute pain management is limited by addiction, tolerance, and dependence risks, motivating development of nonopioid analgesics.
Quoted textsource-backed
Acute pain management has historically been dominated by opioids, whose efficacy is overshadowed by the risks of addiction, tolerance, and dependence, culminating in the global opioid crisis. To transcend this issue, we must innovate beyond opioid-based μ receptor treatments, identifying nonopioid analgesics with high efficacy and minimal adverse effects.
Emerging nonopioid pain-management strategies discussed in the review include gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective unbiased pain assessment and research.
Quoted textsource-backed
Furthermore, we explore emerging strategies, including gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective, unbiased pain assessment and research.
Mechanism-based analgesic targets should be tailored to specific pain conditions including inflammatory, neuropathic, and nociplastic pain.
Quoted textsource-backed
This Review navigates the multifaceted landscape of inflammatory, neuropathic, and nociplastic pain, emphasizing mechanism-based analgesic targets tailored to specific pain conditions.